Fulgent Genetics, Inc. (FLGT) Misses Q2 EPS by 26c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. CDNS
2. AVGO
3. ANT
4. META
5. SSD
6. JBLU
7. PECO
8. AGYS
9. ARES
10. RMBS

Go back to Fulgent Genetics, Inc. (FLGT) Misses Q2 EPS by 26c

Fulgent Genetics Reports Second Quarter Financial Results

August 9, 2021 4:05 PM EDT

Revenue grows 790% year over year to $153.6 million Core Revenue grows 296% year over year to $25.7 million Announces acquisition of CSI Laboratories Announces commercial agreement with Helio Health through strategic investment Announces incremental controlling investment in Chinese Joint Venture entity, FF Gene Biotech

TEMPLE CITY, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent or the company), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its second quarter ended June 30, 2021.

Second... More